Zepbound KwikPen approved and launched in Canada
Health Canada has authorized Zepbound KwikPen, the tirzepatide pen for chronic weight management, giving Canadians the same two-brand tirzepatide split — Mounjaro and Zepbound — already used in the US.
Eli Lilly Canada announced on July 9, 2025, that Zepbound KwikPen (tirzepatide injection) is now available in Canada after Health Canada authorized it on May 13, 2025, as a once-weekly injection for chronic weight management [1]. The approval mirrors the US market structure, where the same molecule, tirzepatide, is sold as Mounjaro for type 2 diabetes and as Zepbound for weight management [1].
Health Canada cleared Zepbound KwikPen as an add-on to diet and exercise for adults with obesity, defined as a body mass index of 30 kg/m2 or higher, or for adults who are overweight, with a BMI of 27 to under 30 kg/m2, who also have at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease [1]. The drug works by activating two hormone receptors, GIP and GLP-1, which Lilly says makes it the first and only Health Canada-approved dual receptor agonist for obesity treatment [1].
The approval rests on four late-stage trials: SURMOUNT-1, SURMOUNT-2, SURMOUNT-3, and SURMOUNT-4 [1]. In SURMOUNT-1, which enrolled 2,539 adults with obesity or excess weight and related conditions but not diabetes, people taking the highest dose, 15 mg, lost an average of 21.8 kg (48 lbs) over 72 weeks, compared with 15.4 kg (34 lbs) at the lowest 5 mg dose and 3.2 kg (7 lbs) among those on placebo [1]. The broader SURMOUNT program has enrolled more than 5,000 people with obesity or overweight across six studies since starting in late 2019 [1].
Lilly Canada frames the launch against a backdrop it says shows obesity is widely undertreated. The company cites Statistics Canada data indicating one in three Canadians live with obesity [1], and a 2025 study in BMC Public Health estimating the economic cost of inaction on obesity in Canada at $27.6 billion, a figure the study's authors say is 20% higher than earlier estimates [1]. Lilly also points to Obesity Canada figures showing 54% of adults with obesity report stigma from coworkers and 64% report experiencing weight bias from a healthcare professional [1].
Why it matters for patients
For US readers, the Canadian launch confirms that tirzepatide's brand split by indication, Mounjaro for diabetes and Zepbound for weight management, is not unique to the US market; Canada has adopted the same approach [1]. That distinction matters for anyone comparing prescriptions, insurance coverage, or drug names across the border, since the active ingredient is identical but the approved use and label differ by brand.
The Canadian label's eligibility criteria, a BMI of 30 or higher, or 27 to under 30 with a weight-related condition, closely track the entry criteria used in the pivotal SURMOUNT-1 trial [1]. Patients weighing their options may find the trial's average weight-loss figures, up to 21.8 kg at the top dose over 72 weeks, useful context, though individual results vary and the sources here do not include long-term data beyond that trial window [1].
The sources do not address pricing, insurance or provincial drug plan coverage in Canada, nor do they compare Zepbound's Canadian availability with US supply or cost. Those details are not yet known from the material provided.
What happens next
Health Canada's authorization was granted May 13, 2025, with commercial availability announced July 9, 2025 [1]. The sources do not specify further regulatory or commercial milestones, such as pricing decisions or public and private insurance reviews, beyond noting that Lilly says it is working to make its medicines more accessible and affordable [1].
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.